The estimated Net Worth of Thomas Malley is at least $2.35 Milhão dollars as of 5 June 2024. Mr. Malley owns over 4,373 units of BeiGene Ltd stock worth over $1,979,109 and over the last 12 years he sold BGNE stock worth over $0. In addition, he makes $373,000 as Non-Executive Independent Director at BeiGene Ltd.
Thomas has made over 7 trades of the BeiGene Ltd stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of BGNE stock worth $923,359 on 5 June 2024.
The largest trade he's ever made was buying 50,000 units of BeiGene Ltd stock on 16 June 2023 worth over $575,000. On average, Thomas trades about 3,316 units every 122 days since 2012. As of 5 June 2024 he still owns at least 9,373 units of BeiGene Ltd stock.
You can see the complete history of Mr. Malley stock trades at the bottom of the page.
Thomas Robert Malley serves as Non-Executive Independent Director of the Company. Mr. Malley has served as president of Mossrock Capital, LLC, a private investment firm, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley received a B.S. in Biology from Stanford University in January 1991. Mr. Malley has held directorships in the following listed companies: • Kura Oncology, Inc., a company listed on the Nasdaq, as a director since 2015; • Kiniksa Pharmaceuticals, a company listed on the Nasdaq, as a director since 2016; • OvaScience, Inc., a company listed on the Nasdaq, as a director from 2012 to 2017; • Synageva BioPharma Corp., a Company listed on the Nasdaq prior to its delisting in May 2015 in connection with the sale of the company, as a director from 2006 to 2015; • Puma Biotechnology, Inc., a company listed on the Nasdaq, as a director from 2011 to 2015; and • Cougar Biotechnology, Inc., a company listed on the Nasdaq prior to its delisting in July 2009 in connection with the sale of the company, as a director from 2007 to 2009.
As the Non-Executive Independent Director of BeiGene Ltd, the total compensation of Thomas Malley at BeiGene Ltd is $373,000. There are 9 executives at BeiGene Ltd getting paid more, with John Oyler having the highest compensation of $13,899,000.
Thomas Malley is 51, he's been the Non-Executive Independent Director of BeiGene Ltd since 2016. There are 12 older and 9 younger executives at BeiGene Ltd. The oldest executive at BeiGene Ltd is Donald Glazer, 75, who is the Non-Executive Independent Director.
Thomas's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd...., eBros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
BeiGene Ltd executives and other stock owners filed with the SEC include: